Halabi S., Lin C.Y., Kelly W.K., Fizazi K.S., Moul J.W., Kaplan E.B., Morris M.J., Small E.J.
Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2014 32:7 (671-677)
Prognostic models for overall survival (OS) for patients with metastatic castration-resistant prostate cancer (mCRPC) are dated and do not reflect significant advances in treatment options available for these patients. This work developed and validated an updated prognostic model to predict OS in patients receiving first-line chemotherapy. Data from a phase III trial of 1,050 patients with mCRPC were used ( Cancer and Leukemia Group B CALGB-90401 [Alliance]). The data were randomly split into training and testing sets. A separate phase III trial served as an independent validation set. Adaptive least absolute shrinkage and selection operator selected eight factors prognostic for OS. A predictive score was computed from the regression coefficients and used to classify patients into low- and high-risk groups…(ver más)